Study of Tauroursodeoxycholic Acid for Hepatobiliary Disease in Cystic Fibrosis
Status:
Completed
Trial end date:
2001-09-01
Target enrollment:
Participant gender:
Summary
OBJECTIVES: I. Determine the optimum dose of tauroursodeoxycholic acid (TUDCA) required to
achieve maximal bioavailability for patients with cystic fibrosis-associated liver disease.
II. Compare optimized doses of TUDCA with ursodiol (ursodeoxycholic acid; UDCA) for effects
on biliary bile acid composition and metabolism, serum biochemistries, fat absorption, and
fat-soluble vitamin status in these patients.